Nanocarrier Lipid Composition Modulates the Impact of Pulmonary Surfactant Protein B (SP-B) on Cellular Delivery of siRNA

Two decades since the discovery of the RNA interference (RNAi) pathway, we are now witnessing the approval of the first RNAi-based treatments with small interfering RNA (siRNA) drugs. Nevertheless, the widespread use of siRNA is limited by various extra- and intracellular barriers, requiring its enc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmaceutics
Main Authors: Guagliardo, Roberta, Merckx, Pieterjan, Zamborlin, Agata, De Backer, Lynn, Echaide, Mercedes, Pérez-Gil, Jesus, De Smedt, Stefaan C., Raemdonck, Koen
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6781292/
https://ncbi.nlm.nih.gov/pubmed/31450805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics11090431
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados